iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes

Almudena Martinez-Fernandez1, Timothy J Nelson1, Santiago Reyes1

  • 1From the Center for Regenerative Medicine (A.M.-F., T.J.N., S.R., A.E.A., A.T.), Marriott Heart Disease Research Program, Division of Cardiovascular Diseases (A.M.-F., S.R., A.E.A., A.T.), and Department of Physical Medicine and Rehabilitation (C.P.-T.), General Internal Medicine and Transplant Center (T.J.N., F.S., R.B.), Mayo Clinic, Rochester, MN; and Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada (H.-K.S., A.N.).

Abstract